• Price (USD)324.21
  • Today's Change-7.67 / -2.31%
  • Shares traded17.24m
  • 1 Year change+328.96%
  • Beta--
Data delayed at least 15 minutes, as of Oct 15 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.

  • Revenue in USD (TTM)7.02bn
  • Net income in USD3.49bn
  • Incorporated2016
  • Employees1.30k
  • Location
    Moderna Inc200 Technology SqCambridge 02139-3578United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Gilead Sciences, Inc.26.64bn5.16bn84.80bn13.60k16.604.3012.,958,677.008.2911.059.9713.3080.1481.9219.2827.471.193.100.604943.079.98-5.43-97.72-63.15-2.7416.09
Zoetis Inc7.41bn1.91bn95.84bn11.30k50.6322.0440.7312.933.993.9915.509.170.54631.336.88655,929.2014.0512.9916.4115.2469.6767.8725.7222.132.5110.710.623121.886.636.979.2037.0315.1319.23
Amgen, Inc.25.48bn5.75bn118.02bn24.30k21.1314.3612.814.639.849.8443.7514.480.40851.585.181,048,724.009.2111.2011.5313.3675.3480.7022.5533.201.039.700.79944.508.833.25-7.370.91970.46715.16
Bristol-Myers Squibb Co44.38bn-5.08bn129.68bn30.25k--3.5222.712.92-2.27-2.2719.6016.570.37164.326.161,467,240.00-4.242.55-5.153.1978.0272.44-11.405.971.42--0.5505192.9562.6220.75-362.14---1.693.99
Moderna Inc7.02bn3.49bn130.87bn1.30k40.4719.4936.4018.648.018.0116.9916.640.7149--6.845,399,735.0035.59--65.71--84.20--49.79--1.17--0.0677--1,234.34---45.34------
AbbVie Inc53.73bn6.60bn193.21bn48.00k29.4315.3712.513.603.723.7230.247.110.36124.955.881,143,170.004.497.735.479.7265.7173.8112.4218.070.78846.490.867197.1537.6914.91-41.90-2.408.4518.50
Data as of Oct 15 2021. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

29.14%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Jun 202145.88m11.37%
The Vanguard Group, Inc.as of 30 Jun 202119.45m4.82%
BlackRock Fund Advisorsas of 30 Jun 202114.29m3.54%
SSgA Funds Management, Inc.as of 30 Jun 20217.33m1.82%
Fidelity Management & Research Co. LLCas of 30 Jun 20216.88m1.70%
Coatue Management LLCas of 30 Jun 20216.14m1.52%
Th�l�me Partners LLPas of 30 Jun 20216.07m1.50%
Morgan Stanley Investment Management, Inc.as of 30 Jun 20214.24m1.05%
Lone Pine Capital LLCas of 30 Jun 20213.99m0.99%
Geode Capital Management LLCas of 30 Jun 20213.36m0.83%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.